Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry

Summary
Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners. Covered by 4 outlets: 4 are not rated.
Automated summary picked from the outlets' own descriptions.
Who is covering this
-
Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry
Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners.
-
Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry
Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners.
-
Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry
Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners.
-
Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry
Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners.
-
Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry
Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners.




Comments
Comments need JavaScript.